Dr. Michael V. Zaretsky, MD
Maternal-Fetal Medicine (High-Risk Pregnancy) (Maternal & Fetal Medicine Physician)
13123 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Northeastern Ohio University College of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Northeastern Ohio University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Maternal & Fetal Medicine Physician primary
CO license DR.0052417 (first issued 2013; active) · TX license K6520 (first issued 1998; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Maternal-Fetal Medicine (High-Risk Pregnancy) per capita by county →
Where they work
Medical groups
- Intermountain Medical Group Grand Junction, LLC (296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 12 payments worth $12,939 in total to this clinician.
| Janssen Research & Development, LLC | $12,939 |
|---|
| Travel and Lodging | $12,597 |
|---|---|
| Food and Beverage | $342 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC Nov 10, 2025 | Travel and Lodging travel to MADRID, Spain · in-kind | $9,020 |
| Janssen Research & Development, LLC Nov 9, 2025 | Travel and Lodging travel to MADRID, Spain · in-kind | $3,429 |
| Janssen Research & Development, LLC Nov 10, 2025 | Travel and Lodging travel to MADRID, Spain · in-kind | $88.20 |
| Janssen Research & Development, LLC Nov 13, 2025 | Travel and Lodging travel to MADRID, Spain · in-kind | $38.72 |
| Janssen Research & Development, LLC Nov 11, 2025 | Travel and Lodging travel to MADRID, Spain · in-kind | $20.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $32,000 in research payments for these studies, mostly to the institutions running them.
- Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Janssen Research & Development, LLC - A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimb in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.